Street Talk: Patent Issues Could Dominate Pharma Industry in 2006 - Proposed reforms on current patent practices could hand pharma substantial losses of revenue and diminished profit margins -

ADVERTISEMENT

Street Talk: Patent Issues Could Dominate Pharma Industry in 2006
Proposed reforms on current patent practices could hand pharma substantial losses of revenue and diminished profit margins


BioPharm International
Volume 19, Issue 1

But Congress is also looking at ways to curb longer patent protection time periods. Right now, biopharmaceutical firms enjoy roughly 20 years of drug patent protection for their brand-name drugs. The Hatch-Waxman Act would limit the automatic extensions filed by drug makers.

So is it too soon to call 2006 the Year of the Patent? Maybe, or maybe not.

But one thing is for sure. For a heads-up on long-term profit margins for big biopharmaceutical companies and the generic drug companies chasing them, patent reform is well worth watching closely.

Celebrity author and business/finance commentator for CNN and Fox News, Brian O'Connell has written for The Wall Street Journal and Newsweek, 79 Radcliffe Drive, Doylestown, PA 18901, 215.230.3711, fax 267.880.1939,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here